$TWST (-2.97%) is showing strong growth momentum with 23% annual sales gain and expanding relevance in synthetic DNA and genomics. Right now, the stock is coming off its recent lows, the biotech sector is heating up again, and Twist’s pipeline positions it for big upside as more labs and developers pivot to synthetic biology platforms. With the tech-driven rebound and innovation tailwinds, this could be a great entry for the next leg higher.
